Revenue of USD 1,406.4 million was generated in the global pyrogen test market for 2023, which is expected to grow at a compound annual growth rate of 7.3% over the period from 2024 to 2030 and reach USD 2,284.2 million. This growth of the market can be credited to the increasing acceptance of pyrogen testing within the biopharmaceutical sector.
Furthermore, the rising development in the biotechnology and pharmaceutical industries along with the increasing count of new biologics research and introductions is projected to fuel the demand for these testing for making safe and better drugs.
Pyrogen testing is a vital step for each medication and therapeutics to make it safer and more effective. Surge in the count of cancer cases and hereditary illnesses, modified treatments attained benefits in the treatment of these diseases.
Tailored medicine has the benefit that it uses people’s hereditary profiles to aid in decision-making for the prevention, diagnosis, and treatment of illnesses. Therefore, patients and businesses are quickly accepting modified drugs. Furthermore, modified treatment-based methods to clinical and genomic features are becoming more popular among patients with cancer and immunologic sicknesses. Hence, the increasing need for modified drugs is one of the key reasons propelling the demand for pyrogen testing solutions.
On the basis of the end user, the category of pharmaceutical and biotechnology companies accounted for the largest revenue share of 35% in 2023 and is expected to remain so in the future. This has been driven by the increase in the manufacturing of medicines, biologics, and new drugs as well as a growing demand for pyrogen testing. In addition, the market growth in this category is being driven by a growing preference for personalized medicine as well as an increasing incidence of infectious and chronic diseases.
The foremost sales generator in 2023, North America accounted for the highest market percentage of 55%. That is due to the continuing growths in biotechnology and pharmaceutical wherein cookies are used to make your experience better. Other key factors that have contributed to the increase of the local marketplace consist of an extended pipeline of prescribed drugs, an upward thrust in drug approvals as well as growing awareness about product safety and food security.
In the North American region, the U.S. dominates the industry. This is mainly because of the existence of advanced healthcare infrastructure, augmented concentration on new drug growth, and the presence of key biotechnology and biopharmaceutical companies, like Pfizer Inc. and F. Hoffmann-La Roche AG, in the country.
Furthermore, Canada is also generating substantial revenue for the North American industry. This can be credited to the rising pharmaceutical and biotechnology sector, the rising awareness regarding the safety of medications, and the growing R&D activities in the country.
Comments